highperformr logo

BenevolentAI's Overview

Total employees131
HeadquartersLondon
Founded2013

BenevolentAI is a clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting-edge science to decipher complex disease biology, identify novel drug targets, and develop new medicines. Their proprietary Benevolent Platform™ aims to accelerate the journey from data to medicine, focusing on areas with high unmet patient needs. By transforming how drugs are discovered, BenevolentAI strives to bring more effective therapies to patients faster and more efficiently.

Where is BenevolentAI's Headquarters?

HQ Function

The London headquarters serves as the central hub for research and development, corporate strategy, AI platform development, and global operations management.

Notable Features:

Modern office space designed for collaboration, housing both computational and scientific teams. Proximity to leading academic institutions and biomedical research facilities.

Work Culture:

A dynamic, innovative, and science-driven environment that encourages cross-disciplinary collaboration between AI specialists, biologists, chemists, and drug developers. Emphasis on continuous learning and tackling complex challenges.

HQ Significance:

Its location in London provides access to a rich talent pool, world-class research institutions, and the European financial markets, supporting its growth and innovation.

Values Reflected in HQ: The headquarters' design and location reflect BenevolentAI's commitment to innovation, collaboration, scientific excellence, and being at the forefront of technological advancement in healthcare.

Location:

BenevolentAI operates with a significant presence in Europe and North America. Its London headquarters drives overall strategy and AI platform development, the Cambridge (UK) site focuses on experimental drug discovery, and the New York office supports US operations and business development. This global footprint enables access to diverse talent pools, research collaborations, and key pharmaceutical markets.

Street Address:

4-8 Maple Street

City:

London

State/Province:

England

Country:

United Kingdom

BenevolentAI's Global Presence

New York, NY, USA

Address: 7 World Trade Center, 250 Greenwich St, New York, NY 10007, USA

To expand BenevolentAI's presence in North America, fostering partnerships, accessing US talent, and engaging with the American financial and biopharma communities.

Cambridge, United Kingdom

Address: Babraham Research Campus, Cambridge, CB22 3AT, UK

To anchor BenevolentAI's experimental science capabilities within one of the world's foremost biotech hubs, facilitating collaborations and access to specialized talent and infrastructure.

Buying Intent Signals for BenevolentAI

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of BenevolentAI

As of April 2025, BenevolentAI' leadership includes:

Dr. Joerg Moeller - Chief Executive Officer
Catherine Isted - Chief Financial Officer (designate, joining Q3 2024)
Nicholas Keher - Chief Financial Officer (until Q3 2024)
Dr. Daniel Neil - Chief Technology Officer
Dr. Ceri Morgan - VP, Drug Discovery
James Thomas - VP, Corporate Development
Christina Unge - VP, Head of Clinical Development

Investors of BenevolentAI

BenevolentAI has been backed by several prominent investors over the years, including:

Temasek
CPP Investments
AstraZeneca (via collaboration and equity investment)
Woodford Investment Management (historical)
Goldman Sachs Asset Management
Various institutional investors post-Euronext Amsterdam listing

Executive New Hires/Exits in the Last 12 Months

Hire2
Exits2

BenevolentAI has experienced key leadership transitions, including the appointment of a new CEO in May 2023 and the announcement of an incoming CFO expected in Q3 2024.

Departures

Joanna Shields (Baroness Shields), Joanna Shields stepped down as CEO.
Nicholas Keher, Nicholas Keher to step down as CFO.

New Appointments:

Dr. Joerg Moeller, Dr. Joerg Moeller appointed as new CEO.
Catherine Isted, Catherine Isted announced as incoming CFO.

Technology (Tech Stack) used by BenevolentAI

Discover the tools BenevolentAI uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

BenevolentAI Email Formats and Examples

BenevolentAI commonly uses the email format combining the employee's first name initial followed by their last name, or first name separated by a dot from the last name, at the benevolent.ai domain. Variations may exist.

[first_initial][last]@benevolent.ai or [first].[last]@benevolent.ai

Format

jdoe@benevolent.ai

Example

80%

Success rate

News and media

BenevolentAI Press ReleaseApril 24, 2024

BenevolentAI news title: BenevolentAI Announces Appointment of Catherine Isted as Chief Financial Officer

BenevolentAI announced the appointment of Catherine Isted as Chief Financial Officer (CFO) and executive Director of the Company. Catherine is expected to join BenevolentAI and the Board in Q3 2024, succeeding Nicholas Keher....more

BenevolentAI Press ReleaseMarch 20, 2024

BenevolentAI news title: BenevolentAI Announces Full Year Results for the Year Ended 31 December 2023

BenevolentAI reported its financial results for 2023, highlighting progress in its pipeline, strategic collaborations, and advancements in its AI platform. Revenue was £10.6 million, primarily from collaborations....more

BenevolentAI Press ReleaseSeptember 26, 2023

BenevolentAI news title: BenevolentAI announces positive topline Phase Ia results for BEN-8744, an oral PDE10 inhibitor for the treatment of Ulcerative Colitis

BenevolentAI announced positive topline results from the Phase Ia first-in-human clinical trial for BEN-8744. The study demonstrated that BEN-8744 was safe and well-tolerated at all dose levels tested....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including BenevolentAI, are just a search away.